LRPPRC-IN-1
LRPPRC-IN-1 is a LRPPRC inhibitor. LRPPRC-IN-1 exerts dual effects of inhibiting LRPPRC activity and inducing its degradation by binding to the RNA-binding domain of LRPPRC. LRPPRC-IN-1 downregulates the expression of mitochondrial OXPHOS complex subunits and ATP synthase, inhibits oxidative phosphorylation, reduces ATP production, suppresses the proliferation and colony formation of various cancer cells, and inhibits tumor growth in vivo. LRPPRC-IN-1 can be used in studies related to lung cancer, pancreatic cancer, breast cancer, esophageal cancer, colorectal cancer, lymphoma, melanoma, cervical cancer, ovarian cancer, and prostate cancer.
For research use only. We do not sell to patients.
- Formula: C21H13Br2F3N2O4
- Molecular Weight:574.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
LRPPRC-IN-1 (compound 3o) (6.25-12.5 μM) potently inhibits the interaction between purified LRPPRC protein and its aptamer, with an inhibition rate of over 92.5%[1].
LRPPRC-IN-1 (5-10 μM) induces significant concentration-dependent degradation of LRPPRC protein in human lung adenocarcinoma cell line A549, with a maximum degradation rate of approximately 70%[1].
LRPPRC-IN-1 (120 h) exhibits potent and broad-spectrum antiproliferative activity against a variety of human cancer cell lines, with IC50 values ranging from 0.27 μM to 8.33 μM, including high activity against drug-resistant and refractory tumors[1].
LRPPRC-IN-1 (1.25-20 μM; 14 days) potently inhibits colony formation in a variety of human cancer cell lines[1].
LRPPRC-IN-1 (0.0-1.6 nM) inhibits the protein level of LRPPRC as well as the protein and transcription levels of the downstream mitochondrial OXPHOS signaling pathway in human lung adenocarcinoma cell line A549 at nanomolar concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Multiple human cancer cell lines: A549, PC9, A2780, MKN45, MDA-MB-231, SUM159, BXPC-3, ASPC-1
-
Concentration:1.25 μM, 2.5 μM, 5 μM, 20 μM
-
Incubation Time:14 days
-
Result:Completely inhibited colony formation of A549, PC9, A2780, and MKN45 cells at 20 μM.
Significantly suppressed colony formation of MDA-MB-231, SUM159, BXPC-3, and ASPC-1 cells at concentrations of 1.25 μM, 2.5 μM, and 5 μM.
-
Cell Line:A549 cells
-
Concentration:0.0 nM, 0.4 nM, 0.8 nM, 1.6 nM
-
Incubation Time:48 h
-
Result:Significantly downregulated the transcription of OXPHOS-related genes, including COXI, COXII, and ATP6.
Parmacokinetics
| Species | Dose | Route | Tmax | T1/2 | Cmax | AUC0-t | AUC0-∞ | MRT0-∞ | F | Vss | CL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.v. | / | 4.26 h | / | 13400 ng·h/mL | 13600 ng·h/mL | 5.17 h | / | 1.90 L/kg | 6.12 mL/min/kg |
| Mice[1] | 5 mg/kg | i.p. | 0.5 h | 4.04 h | 6000 ng/mL | 22800 ng·h/mL | 23200 ng·h/mL | 5.89 h | 170.6 % | / | / |
| Mice[1] | 10 mg/kg | p.o. | 1.0 h | 4.35 h | 492 ng/mL | 4780 ng·h/mL | 4870 ng·h/mL | 6.31 h | 17.9 % | / | / |
In Vivo
LRPPRC-IN-1 (50 mg/kg; i.p.; daily; 10 days) exhibits significant in vivo antitumor activity against HCT116 xenografts, achieving a 49% tumor growth inhibition rate with a favorable safety profile[1].
LRPPRC-IN-1 (25-100 mg/kg; p.o.; daily; 10 days) exhibits a tolerable in vivo safety profile in healthy BALB/c mice at doses conferring antitumor efficacy, with only mild, dose-related alterations in select plasma biochemical markers at the highest tested dose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-Nu nude mice (4-6 weeks old, male) were used to establish a xenograft model by inoculating PC9 cells.
[1] -
Dosage:50 mg/kg
-
Administration:i.p.; daily; 18 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 73%.
Reduced tumor volume and tumor weight significantly.
Maintained stable mouse body weights throughout the treatment period.
-
Animal Model:BALB/c-Nu nude mice (4-6 weeks old, male) were used to establish a xenograft model by inoculating HCT116 cells.[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 49%.
Suppressed tumor growth significantly.
Maintained stable mouse body weights across all treatment groups.
-
Animal Model:BALB/c mice[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 10 days
-
Result:Showed favorable liver safety with no significant alterations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), or albumin (ALB) levels at any dose.
Caused a slight decrease in γ-glutamyl transferase (GGT) in the 100 mg/kg group.
Induced mild increases in uric acid (UA) and lactate dehydrogenase (LDH) at 100 mg/kg.
Chemical Information
-
Molecular Weight 574.14
-
Formula C21H13Br2F3N2O4
-
SMILES
O=C(C1=CC=C(C=C1O)C2=C(C=CC=C2)C(F)(F)F)N/N=C/C3=CC(Br)=C(C(Br)=C3O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)